वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Boston Scientific Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $64.5B | |
|---|---|---|
| Revenue (ttm) | 21.1B | |
| Net income (ttm) | 3.5B | |
| EPS (ttm) | $2.37 | |
| Shares out | 1.4B | |
| P/E (trailing) | 17.8x | |
| P/E (forward) | 13.2x | |
| Volume | 66,508,095 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B | +14.0% |
| Gross profit | $8.18B | $8.73B | $9.90B | $11.49B | $13.85B | +14.1% |
| Operating income | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B | +31.8% |
| Net income | $1.04B | $698.0M | $1.59B | $1.85B | $2.89B | +29.1% |
| EPS (diluted) | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | +29.5% |
| EBITDA | $2.52B | $2.74B | $3.45B | $3.94B | $5.10B | +19.3% |
| R&D | $1.20B | $1.32B | $1.41B | $1.62B | $2.05B | +14.3% |
| SG&A | $4.36B | $4.52B | $5.19B | $5.98B | $6.89B | +12.1% |
Recent company headlines from major financial publishers.
In the bull case, rapid clinical adoption of pulsed field ablation in international territories outpaces expectations, while FARAPULSE Ultra and ICE achieve broad commercial availability ahead of schedule in early 2027. Standalone WATCHMAN volume contraction reverses quickly as clinical education programs and 3-year CHAMPION trial data reassure physicians,. Annual diluted EPS growth reaches 14.5% to 15.0%, and operating margins expand toward top-tier peer levels.
The base case models management's updated FY2026 organic revenue guidance of 5% to 6% and consensus EPS of $3.24. In FY2027, revenue advances 4.85% with EPS of $3.38 as product mix headwinds linger and Penumbra is integrated. Commencing in FY2028, revenue growth accelerates to 7.5% and operating margins reach 28.5% by FY2030 as FARAPULSE Ultra scales and $500M in efficiency savings are realized,.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 7.0% | $73.0 | $75.7 | $78.6 | $82.0 | $85.9 |
| 7.5% | $67.2 | $69.3 | $71.6 | $74.2 | $77.1 |
| 8.0% | $62.5 | $64.1 | $65.9 | $68.0 | $70.2 |
| 8.5% | $58.5 | $59.8 | $61.3 | $62.9 | $64.7 |
| 9.0% | $55.1 | $56.2 | $57.4 | $58.7 | $60.1 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
